Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
VGF CRISPR Activation Plasmid (m): sc-436316-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VGF CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- VGF CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by VGF CRISPR Activation Plasmid (m) and VGF CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Vgf transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: VGF Antibody (B-8): sc-365397
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VGF CRISPR Activation Plasmid (m) | sc-436316-ACT | 20 µg | $397.00 |
Vgf encodes VGF, a neuroendocrine secretory granule protein that is proteolytically processed into bioactive peptides influencing neuronal excitability, synaptic plasticity, and neuroendocrine communication. In mouse tissues, VGF expression is induced by trophic signals and activity-dependent transcriptional programs, linking it to pathways that regulate energy balance, stress responses, and neurogenesis. VGF-derived peptides modulate neurotransmitter release and metabolic homeostasis through interactions with neuropeptide signaling networks and downstream cAMP/PKA- and MAPK-associated processes. Dysregulated Vgf expression has been associated with altered mood- and cognition-related phenotypes, metabolic dysfunction, and broader neurodegenerative and neuropsychiatric disease-relevant states in experimental models.
VGF CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Vgf expression without altering the underlying DNA sequence.
VGF CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Vgf locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Vgf transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous VGF expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Vgf locus and enabling the study of VGF-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of VGF pathway restoration in tumor cells with silenced or reduced Vgf expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.